We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Medical Center Collaborates with GenomeQuest

By LabMedica International staff writers
Posted on 14 Jan 2013
GenomeQuest, Inc. More...
(Westborough, MA, USA) a leader in sequence data management, and Beth Israel Deaconess Medical Center (BIDMC; Boston, MA, USA), a Harvard Medical School teaching hospital, are entering into a two-year collaboration to develop whole-genome analysis (WGA) applications for personalized health care. The announcement was made during the opening session of the World Health Forum, held at Harvard Medical School, on December 20, 2012, in Boston (MA, USA).

GenomeQuest will provide whole-genome data management and analysis capabilities for all next-generation sequencing projects in BIDMC’s dept. of pathology. GenomeQuest will also provide application programming interface (API) access and training to the department’s scientific investigators and applied mathematicians. BIDMC pathologists will develop clinical grade annotation methods and databases for diagnoses of cancers and other diseases. Collaborative projects will span user interface, workflows, sequence, and annotation management, and integration into health care Information Technology (IT) systems.

“The latest PriceWaterHouseCoopers report on personalized medicine estimates that this market will grow to nearly $500 billion in 2015 and terms it a ‘disruptive innovation’ for life sciences,” explained BIDMC chief of pathology Jeffrey Saffitz, MD, PhD. “The BIDMC pathology department is already a national leader in the development and application of genomics for personalized medicine, having launched its Genomic Medicine Training Initiative one year ago, and, this past spring, issuing a ‘Call to Action’ for pathology training programs across North America to do the same. Our collaboration with GenomeQuest helps provide us with the infrastructure to continue this work.”

Beth Israel Deaconess Medical Center is clinically affiliated with the Joslin Diabetes Center and is a research partner of the Dana-Farber/Harvard Cancer Center. The core technology of GenomeQuest is the GQ-Engine–a sequence database engine that is purpose-built for storing, managing, and analyzing sequence data at whole- and multigenome scale.

Related Links:
GenomeQuest, Inc.
Beth Israel Deaconess Medical Center


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Portable Electronic Pipette
Mini 96
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.